Eris Lifesciences Ltd has approved acquisition of the remaining 30% stake in Swiss Parenterals Ltd for ₹423.30 crore through issuance of up to 23.06 lakh equity shares, making Swiss a wholly-owned subsidiary.
Source: Eris Lifesciences Limited Press Release (NSE Exchange Fillings) | Published on Nov 24, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release of Eris Lifesciences (NSE Exchange Filings), at its board meeting on Monday, November 24, 2025, the company’s board approved the purchase of the remaining 30% equity in its subsidiary Swiss Parenterals Limited from Mr Naishadh Shah, a director of Swiss and a related party. The acquisition is to be made in non-cash consideration in the form of issue of up to 23,06,372 equity shares of Eris on a preferential basis at an issue price of ₹1,835.35 per equity share for a total of ₹423.30 crore. The company is expecting the acquisition to be completed by March 31, 2026.
Also read: Ceigall India Gets ₹58.5 Crore Contract for Velgaon Substation
The acquisition target is Swiss Parenterals Ltd: 16,74,493 shares representing 30% of its share capital.
Consideration: ₹423.30 crore, discharged via issuance of up to 23.06 lakh shares of Eris Lifesciences.
Issue price: ₹1,835.35 per share on preferential basis.
The transaction qualifies as a related-party transaction, as Swiss Parenterals is a subsidiary and the seller is a director of Swiss.
No promoter or promoter-group of Eris has interest in the transaction beyond this stake acquisition.
The acquisition aims at 100% ownership of Swiss Parenterals Ltd.
Timeline: The company expects completion of the transaction by 31 March 2026.
Also read: Surya Roshni Bags ₹105.18 Crore Spiral Pipe Contract in Gujarat
Parameter | Details |
Target Entity | Swiss Parenterals Ltd |
Existing stake held by Eris | 70% |
Additional stake to acquire | 30% (16,74,493 shares) |
Total consideration | ₹423.30 crore |
Mode of payment | Preferential issuance of up to 23,06,372 equity shares |
Issue price per share | ₹1,835.35 |
Nature of transaction | Related-party transaction at arm’s length |
Expected completion timeline | By 31 March 2026 |
As a result of the acquisition, Swiss Parenterals will become a fully-owned subsidiary of Eris Lifesciences. The rationale for the transaction is to rightsize control, consolidate financials, and align operations in the pharmaceutical business, stated in the filing. Established on 4 February 1997, Swiss Parenterals operates in the parenterals sector, and does so in over 80 countries. Its revenue for the last three financial years was ₹220.80 crore (FY 2022-23), ₹282.97 crore (FY 2023-24), and ₹351.11 crore (FY 2024-25).
In accordance with the transaction payment structure, a share-swap will take place rather than a cash outflow, which allows for the preservation of liquidity amidst the consolidation. Shareholder approval will be required for the preferential issue via postal ballot; 21 November 2025 will be the cut-off date to determine voting eligibility.
The disclosure, made in compliance with Regulation 30 and Regulation 51 (Part A & Part B of Schedule III) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, provides all the necessary details in relation to the acquisition, including the nature of the transaction, consideration, related-party status and timeline for closing. The company has also relied upon the SEBI Master Circular dated 11 November 2024 for disclosures relating to the issue of shares and acquisitions.
Eris Lifesciences share price stands at ₹1,666.00 per share on the BSE as of 24 November 2025 at 15:30 PM IST, down by 0.22%.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading